23d • General discussion
The Cagri-Reta stack optimizer!
❇️ The Cagri-Reta stack is one of the most frequently talked about because as we know Reta is a fat metabolism powerhouse but falls short when it comes to appetite suppression.
👉🏼 The idea behind the protocol is very simple: eliminate hunger and food cravings.
❇️ This stack is the most talked about it's easily one one of the mots misunderstood as well. Most people start by copying random recommendations from online forums which leaves most wiped out.
🔸 Quick takeaways:
- Cagri-Reta combines Cagrilintide (an amylin analogue) with Retatrutide (a triple incretin agonist), leading to a significant impact on satiety and energy expenditure through multiple independent pathways.
- No human trials have directly studied this combination, meaning all dosing advice is extrapolated from individual compound data and clinical trials.
- Slow, conservative dose escalation is non-negotiable with this stack.
- The gastrointestinal side effect burden is dose-dependent, i. e. pushing too hard and too fast will only derail your results.
❇️ What is Cagri-Reta and why are people using this stack???
🔸 Cagrilintide - is a long-acting amylin analogue that activates amylin receptors. - specifically calcitonin receptor and receptor activity-modifying protein (RAMP) complexes - within the area postrema and hypothalamus.
➡ The end result is a reduction in appetite and delayed gastric emptying.
🔸 Retatrutide - is a triple receptor agonist at the GLP-1, GIP and glucagon receptors. It leads to simultaneous suppression of appetite, enhancement of insulin secretion, and an increase energy expenditure through glucagon-mediated thermogenesis.
NOTE: While the mechanisms re complementary and potentially synergistic, they don't completely overlap with one another. Retatrutide monotherapy produced up to 24% weight loss at 48 weeks in Phase 2 trials, which is staggering even by modern standards for pharmacological weight loss.
When you layer in an amylin analogue working through entirely different central satiety pathways, you generate an additive effect signal neither peptide on its own can replicate.
❇️ What Most People Get Wrong About Cagri-Reta Dosing:
➡ Most people look at the highest doses used in the Phase 2 trials investigating Retatrutide, and treat them as starting points instead of endpoints reached after months of careful escalation.
➡ What they fail to realize is both Cagrilintide and Retatrutide were studied using gradual dose-escalation protocols designed to manage gastrointestinal side effects.
➡ Nausea, vomiting, and diarrhea are the primary factors limiting the use of both compounds.
➡ The gastrointestinal side effect burden is dose-dependent AND additive when these compounds are combined. This means the window between “effective” and “miserable” narrows sharply when stacking them.
➡ There is also the glucagon receptor component to take into consideration: Glucagon receptor agonism can elevate resting heart rate and potentially one’s blood pressure levels, which creates a cardiovascular concern for select populations.
👉🏼 Thus, the key to success with this stack is to avoid reaching for the max doses from Day 1.
💉 Cagri-Reta Blend Dosage: An Extrapolated Framework
⚠️ To be completely clear, no published human trials have directly evaluated the Cagrilintide & Retatrutide stack.Nor does anyh peer-reviewed literature define the maximum dose of both peptides for safe use when used in combination (i.e. before the risks outweigh the benefits).
❇️ Every dosing framework for this stack is extrapolated from clinical trial data and the existing research we have on the cagrilintide - semaglutide stack.
✅ Here is a rational and conservative extrapolation framework grounded in what we know…
🔸 Retatrutide Starting Range (Once-weekly subcutaneous injection):
- Start at 0.5 mg per week
- Titrate up by 0.5 to 1 mg every 4 weeks, but ONLY when it is necessary to do so
- For context: The Phase 2 trial doses ranged from 1 mg to 12 mg weekly
- The practical optimization range: 4 to 8 mg weekly for most individuals (according to what clinical trial data reveals)
🔸 Cagrilintide Starting Range (Weekly Subcutaneous):
- Start at 0.16 mg per week (matching what was done in the clinical trials)
- Titrate up by by 0.16 to 0.3 mg every 4 weeks, but ONLY when it is necessary to do so
- For context: The Phase 2 trial doses for Cagrilintide were as high as 4.5 mg weekly in combination studies
- The practical dosing range when stacked with another hunger-suppressing peptide: 0.5 to 2.4 mg weekly
⚠️ The critical stacking principle to abide by:
➡ Start with Retatrutide first, and DO NOT begin Cagrilintide until Retatrutide is stable and well-tolerated at a dose you have held for at least four weeks.
What you’re effectively doing here is using two compounds with overlapping GI mechanisms.
For that reason, staggering their introduction is the smarter and safer approach
NOTE: The standalone Cagrilintide protocol runs at 250 mcg dosed three days per week, which lands around 750 mcg weekly total. This would be appropriate in the context of Cagrilintide monotherapy.
But once you start stacking it with Retatrutide, the starting point is deliberately lower and dose escalations happen much less frequently.
🚨 Cagri-Reta Safety, Risks, and Contraindications
➡ Gastrointestinal adverse events (nausea, vomiting, diarrhea, etc.) are the most common side effects (and are also dose-dependent). They are confirmed across all human trial data for both compounds, and will certainly be amplified with these peptides are used in combination.
➡ GLP-1-based therapies carry an established association with increase gallbladder disease risk and rare pancreatitis (although they are extremely rate and easy to mitigate/prevent), and this observation likely extends to Retatrutide as well.
➡ In particular, the glucagon receptor activation inherent with the use of Retatrutide may increase resting heart rate and blood pressure readings. Therefore, you may require cardiovascular marker monitoring before, during, and after using the Cagri-Reta stack.
➡ Cagrilintide markedly slows gastric emptying, which can alter the absorption and plasma levels of oral medications you may be taking concurrently.
➡ Additionally, long-term safety data for Retatrutide beyond Phase 2 trials has yet to be published.
❇️ This is a frontier-breaking compound and must be treated as such.
⚠️ Two more things to be mindful of:
- NEVER use this stack without baseline and ongoing labs: fasting glucose, HbA1c, lipids, liver enzymes, kidney function, and resting heart rate monitoring at minimum.
- DO NOT use this combination if you have a personal or family history of medullary thyroid carcinoma, pancreatitis, or serious cardiovascular disease without direct physician oversight.
✅ Summary:
➡ The Cagri-Reta stack is a genuinely novel approach to metabolic optimization.
It hits the amylin receptors, GLP-1 receptors, GIP receptors, and glucagon receptors simultaneously across complementary satiety and energy expenditure pathways.
➡ The currently available science supports the logic behind combination therapy at a mechanistic level, and the extrapolated dosing framework is grounded in the best available human trial data for each compound individually.
➡ But this is groundbreaking territory, and you must approach this stack with an open and curious mind.
➡ Start at the lowest doses possible, escalate them slowly when required, and monitor how your body responds to each peptide.
📣 DO NOT combine Retatrutide and Cagrilintide until each compound is individually stable and tolerated.
3
3 comments
The Cagri-Reta stack optimizer!
powered by
skool.com/peptide-resource-center-3431
We are here for you because we've been there. Get support, education, resources and more!!!
Suggested communities
Powered by